Table 3 The ORR and mTTSP of patients who received one line of chemotherapy before PARPi maintenance therapy based on BRCA status and PFI in the PS group
PFI ≥ 6 months | 6 ≤ PFI < 12 months | PFI ≥ 12 months | ||||
|---|---|---|---|---|---|---|
ORR (%) | mTTSP (95%CI) (month) | ORR (%) | mTTSP (95%CI) (month) | ORR (%) | mTTSP (95%CI) (month) | |
BRCA mutations (n = 12) | 16.7 | 7.1 (4.9–9.1) | 0 | 4.2 (2.7–5.3) | 40 | 9.1 (6.9–11.1) |
BRCA wild–type (n = 18) | 33.3 | 6.2 (3.7–8.3) | 23.1 | 5.1 (2.0–7.1) | 60 | 10.1 (1.4–18.6) |
Total (n = 30) | 26.7 | 7.1 (5.4–8.6) | 15 | 5.1 (3.6–6.4) | 50 | 10.0 (5.9–12.1) |